Fenretinide in Treating Patients With Leukoplakia of the Mouth
Completed · Phase 2 · Has a placebo group
Conditions studied: Head and Neck Cancer
In brief
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development of or treat early cancer. Fenretinide may be an effective drug in treating leukoplakia. PURPOSE: Randomized phase II trial to study the effectiveness of fenretinide in treating patients who have leukoplakia of the mouth.
Key facts
- Study ID
- NCT00004161
- Run by
- University of Alabama at Birmingham
- People needed
- 30
- Starts
- 1997-06-01
- Expected to finish
- 2004-01-01
- Last updated by the study team
- 2013-04-12
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of Alabama Comprehensive Cancer Center — Birmingham, Alabama, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.